Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Simone Chang

Pediatric Hematology-Oncology Tampa, FL Medical Doctor

NPI 1588010953 CMS profile 7232233

2 Tampa General Cir, Tampa, FL 33606

Open in the dashboard

General payments

$2,328

31 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Simone Chang of Tampa, FL is reported in the CMS Open Payments database as having received $2,328 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $260 2
2024 General $141 3
2023 General $333 8
2022 General $285 6
2021 General $1,090 10
2020 General $218 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Simone Chang
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Simone Chang were reported at $260. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Simone Chang Pediatric Hematology-Oncology median Middle half National median
2019 $0 $184 $69–$2,094 $163
2020 $218 $220 $37–$3,941 $114
2021 $1,090 $366 $63–$4,909 $132
2022 $285 $181 $66–$2,775 $149
2023 $333 $175 $62–$2,600 $160
2024 $141 $227 $66–$2,992 $164
2025 $260 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Eisai Inc. $303 3 payments
  2. Jazz Pharmaceuticals Inc. $260 2 payments
  3. Incyte Corporation $236 2 payments
  4. Amgen Inc. $234 2 payments
  5. Rigel Pharmaceuticals, Inc. $172 2 payments
  6. Fennec Pharmaceuticals, Inc. $157 2 payments
  7. Genzyme Corporation $127 1 payment
  8. Adaptive Biotechnologies Corporation $127 1 payment
  9. Global Blood Therapeutics, Inc. $110 1 payment
  10. Pharmacyclics LLC, An AbbVie Company $105 1 payment
  11. Other $497 14 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,328 31 payments
Products named General payments · program years 2020–2025
  1. Lenvima $303 3 payments
  2. RYLAZE $260 2 payments
  3. Blincyto $234 2 payments
  4. Tavalisse $172 2 payments
  5. Pedmark $157 2 payments
  6. LIBTAYO $127 1 payment
  7. clonoSEQ $127 1 payment
  8. MONJUVI $123 1 payment
  9. JAKAFI $114 1 payment
  10. OXBRYTA $110 1 payment
  11. Other $593 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record